Stocktoria
Tango Therapeutics, Inc. TNGX
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2020-09-03
Tango Therapeutics, Inc. financials (annual)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $62.4M | $42.1M | $36.5M | $24.9M | $37.0M | $7.7M |
| R&D expense | $132.2M | $143.9M | $115.2M | $105.9M | $77.6M | $50.0M |
| Operating income | -$111.3M | -$145.6M | -$114.2M | -$111.1M | -$58.2M | -$52.2M |
| Income tax | $4,000 | $208,000 | $134,000 | $54,000 | $292,000 | $0 |
| Net income | -$101.6M | -$130.3M | -$101.7M | -$108.2M | -$58.2M | -$52.0M |
| EPS (diluted) | $-0.87 | $-1.19 | $-1.08 | $-1.23 | $-0.94 | — |
| Operating cash flow | -$138.9M | -$131.5M | -$118.0M | -$109.1M | -$59.5M | $70.1M |
| Free cash flow | -$139.9M | -$132.3M | -$119.5M | -$116.8M | -$61.4M | $69.0M |
| Cash & equivalents | $112.3M | $69.5M | $66.4M | $60.0M | $142.7M | $28.4M |
| Total assets | $398.7M | $316.5M | $402.6M | $436.5M | $500.2M | $207.3M |
| Total liabilities | $52.5M | $117.0M | $149.5M | $187.0M | $155.4M | $168.7M |
| Shareholders' equity | $346.2M | $199.5M | $253.1M | $249.5M | $344.7M | $38.6M |
Growth · year-over-year · Revenue CAGR 52.1%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue growth | +48.3% | +15.2% | +46.9% | -32.9% | +383.8% | — |
| Free cash flow growth | — | — | — | — | -189.0% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.